Inhibition of DNMT activity (mainly DNMT1) in breast, colon, prostate, and esophageal cancer cells [61]Inhibition of hTERT promoter methylation in breast, lung, oral cavity, liver, and thyroid tumor cells [61]Demethylation of SCUBE2 promoter, inhibiting the epithelial-mesenchymal transition [80]Modulation of HAT activity [60]Regulation of miRNA expression in hepatocellular carcinoma and gastric cancer in vivo, targeting c-Kit, Bcl2, E2F, and RAS [62]. This evidence concerns the gene KIT and esophageal cancer.